SL Insight Newsletter #39

An analysis of the FOPH’s SL database (as of June 1, 2026) reveals a significant shift in the pricing of original products newly added to the Specialty List.

‍

‍

‍

‍

What are the key points?

‍

• The share of new originator drugs with a confidential pricing model remained stable at around 25% from 2018 to 2023 and has been just over one-third since 2024
• In oncology and immunology (ATC-L), approximately 70% of new originator drugs have recently adopted a pricing model

‍

What's the story behind this?

‍

While the number of new SL launches of innovative original products is at a record high (75 new products in 2025), what is changing is the pricing structure: the listed factory price is kept high and shielded by a confidential discount against international pricing (MFN/GENEROUS).

‍